Clinical trial · Observational
Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics
NCT04966962CI-TRIAL-00052750unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Metabolomics is a complementary approach for identifying perturbed metabolic pathways. The goal of this study is to establish and validate an early diagnostic model for bladder cancer by metabolomics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum and urine metabolomics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Bladder cancer
- description
- Patients who diagnosis with incident or recurrent bladder cancer
- interventionNames
- Diagnostic Test: serum and urine metabolomics
- label
- benign disease of urinary system
- description
- Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
- interventionNames
- Diagnostic Test: serum and urine metabolomics
Primary outcomes (2)
- measure
- Sensitivity
- timeFrame
- 1 year
- description
- Measurement the sensitivity of diagnostic model based on urine and serum metabolomics in differentiating between bladder cancer and benign disease of the urinary system
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Bladder cancer group: 1. Any male or female patient aged 18 or older 2. Able to provide serum and urine specimen before treatment 3. Diagnosis with incident or recurrent bladder cancer Control group 1. Any male or female patient aged 18 or older 2. Able to provide serum and urine specimen before treatment 3. Diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia. Exclusion Criteria: 1. Kidney and liver dysfunction. 2. Incomplete clinical information and laboratory test result 3. Tumor-related treatment was received preoperatively 4. Preoperative routine examination and medical history indicate a history of diabetes, hyperlipidemia and other metabolic diseases or other malignant tumors
References
Publications (0)
Data not yet available
No reference posted for this study.